Orforglipron (Foundayo): Lilly's Oral GLP-1 Pill — FDA Approval, Trial Results, and What to Expect

FDA status (updated 2026-05-28): Approved. The FDA approved orforglipron under the brand name Foundayo on April 1, 2026 — the first new molecular entity approved under the National Priority Voucher Program, and the first oral GLP-1 pill for weight loss that can be taken without food or water restrictions. LillyDirect began shipping on April 6, 2026. We update this section within 24 hours of any FDA action.

For roughly five years, every conversation about GLP-1 drugs eventually arrived at the same objection: needles. Semaglutide works. Tirzepatide works better. But a weekly injection is a non-starter for a meaningful slice of the population that would otherwise benefit. Rybelsus — the oral peptide semaglutide — offered an answer, except that it came with a strict set of conditions: take it on an empty stomach, with precisely four ounces of water, and wait thirty minutes before eating or drinking anything else. Not a needle, but not nothing.

Orforglipron is a different answer. It is not a peptide. It does not need an absorption enhancer. You take it once a day, whenever, with however much water you want, with or without food. And the clinical data is substantive enough that the FDA approved it 294 days ahead of its original PDUFA date — the fastest approval of a new molecular entity since 2002.

What orforglipron is — and what makes it structurally different

Most GLP-1 drugs on the market are modified peptides: engineered versions of a naturally occurring hormone, large enough that the digestive system cannot simply absorb them across the gut wall without help. Injectable semaglutide is fatty-acid conjugated to survive in the bloodstream for a week. Oral semaglutide (Rybelsus) pairs the peptide with SNAC, a permeation enhancer that allows a small fraction to absorb if conditions are exactly right.

Orforglipron is a non-peptide small molecule. It was synthesised from scratch to fit the GLP-1 receptor binding pocket without being a fragment of the GLP-1 hormone itself. That structural difference has a straightforward practical consequence: a small organic molecule can pass through the gut wall via conventional oral absorption routes, without a chaperone, without fasting constraints.

The mechanism at the receptor level is the same class action that defines every GLP-1 drug. For a full explanation of that mechanism — glucose-dependent insulin secretion, gastric emptying, central satiety signalling — see our article on how GLP-1 drugs work. What is worth noting for orforglipron specifically is that research published in MDPI's Pharmaceuticals indicates the molecule exhibits partial G protein-biased agonism, robustly activating cAMP signalling while limiting beta-arrestin recruitment and receptor internalisation. In plain terms: it activates the receptor's most therapeutically useful pathways while potentially reducing one mechanism thought to contribute to receptor downregulation. The clinical relevance of that bias is still being characterised.

The ATTAIN Phase 3 programme

Lilly ran two registrational trials for the obesity indication, together enrolling more than 4,500 participants. The complete ATTAIN-1 results were published in The New England Journal of Medicine in 2026.

ATTAIN-1

The core obesity trial ran for 72 weeks. Participants were randomised to orforglipron at 6 mg, 12 mg, or 36 mg (titrated up progressively from a starting dose), or placebo. All three dose arms met the primary endpoint.

Secondary endpoints showed improvements in systolic blood pressure, triglycerides, LDL cholesterol, and HDL cholesterol. The trial was not powered or designed to test cardiovascular outcomes — that data does not exist yet (see the limitations section below).

ATTAIN-MAINTAIN

A separate Phase 3b trial examined a question with real-world significance: what happens to patients who are already on injectable semaglutide or tirzepatide and switch to the oral pill? Dropout from injectables is a documented issue, and the ability to transition rather than stop entirely matters for long-term outcomes.

In ATTAIN-MAINTAIN, participants who switched from semaglutide to orforglipron maintained their previously achieved weight loss with an average difference of only 0.9 kg. Those switching from tirzepatide maintained loss with an average difference of 5 kg — a larger gap reflecting tirzepatide's higher baseline efficacy, but still representing maintenance rather than regain. Results were published in Nature Medicine in 2026.

ACHIEVE programme (type 2 diabetes)

The ACHIEVE trials tested orforglipron in patients with type 2 diabetes. ACHIEVE-3, a head-to-head trial against oral semaglutide (Rybelsus), was published in The Lancet in February 2026, enrolling 1,698 participants. Orforglipron 36 mg reduced HbA1c by 2.2 percentage points versus 1.1 for Rybelsus 7 mg and 1.4 for Rybelsus 14 mg. Weight loss at 52 weeks was 9.2% for orforglipron 36 mg versus 5.3% for Rybelsus 14 mg. Orforglipron met the pre-specified superiority threshold on both co-primary endpoints.

The trade-off: discontinuation due to adverse events was roughly double in the orforglipron arms (8.7–9.7%) compared to Rybelsus (4.5–4.9%). The FDA approved orforglipron for weight management; the type 2 diabetes indication may require a separate NDA submission.

Side effects: what the trial data shows

GI side effects are the class hallmark. Orforglipron is no exception. The ATTAIN-1 data, as reported in the NEJM publication and confirmed by systematic review:

Events were described as mostly mild to moderate in severity and concentrated during dose escalation periods rather than at steady state. Discontinuation due to adverse events: 5.3% (6 mg), 7.9% (12 mg), 10.3% (36 mg) versus 2.7% for placebo.

A 2026 meta-analysis in PMC confirmed the pattern: treatment discontinuation risk ratios were highest at 24 mg (RR 4.61) and 36 mg (RR 3.68). Serious adverse events and mortality were comparable to placebo across all doses — the tolerability issue is real but the safety signal is not alarming.

One label-specific warning: the drug slows gastric emptying enough to reduce oral contraceptive absorption. The FDA prescribing information requires patients using oral hormonal contraceptives to use an additional backup method (non-oral or barrier) for 30 days after initiation and for 30 days after each dose escalation. Non-oral contraceptives — patch, ring, injection, IUD — are unaffected.

Standard class contraindications apply: Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), consistent with other GLP-1 receptor agonists. Per the FDA label, discuss your full medication and medical history with your prescriber before starting.

Orforglipron versus injectables and other oral options

The honest comparison looks like this:

Versus injectable semaglutide (Wegovy)

Wegovy at 2.4 mg weekly produces approximately 15% body weight reduction over 68 weeks in the STEP-1 trial — roughly three percentage points more than orforglipron's top dose. Wegovy also carries a cardiovascular outcomes label (SELECT trial, 2023), showing 20% relative risk reduction in MACE in patients with existing cardiovascular disease. Orforglipron has no equivalent cardiovascular outcomes data yet.

Convenience runs the other way: no needle, no injection site reactions, no cold storage requirements, no restriction on meal timing. For patients deterred by the injection format, or who have travel or schedule constraints that make weekly injections difficult, that is a meaningful difference.

For a full comparison of Wegovy versus other options, see our Wegovy vs Zepbound comparison.

Versus injectable tirzepatide (Zepbound)

Tirzepatide (dual GLP-1/GIP agonist) is the current efficacy leader at 15–22% weight loss across SURMOUNT trials. Orforglipron does not close that gap. Tirzepatide also has the SURMOUNT-CVOT trial underway for cardiovascular outcomes data.

For self-pay patients, the price gap is now narrow. LillyDirect Zepbound vials: $299–$449/month depending on dose (as of May 2026). Foundayo: $149/month. That $150–$300/month gap may be meaningful for long-term adherence. Whether it offsets the efficacy difference is a conversation for patient and prescriber.

Versus oral semaglutide (Rybelsus/Wegovy Pill)

This is where orforglipron's structural advantage is most pronounced. The Wegovy Pill (oral semaglutide approved for obesity in late 2024) requires the same SNAC-dependent fasting protocol as Rybelsus. As one user in r/Ozempic noted: “I’m currently on the wegovy pill and have noticed effectiveness changes based on if I eat food 30 mins after vs an hour or longer.”

Orforglipron has no such constraint. The ACHIEVE-3 head-to-head trial demonstrated superiority to oral semaglutide on both A1c reduction and weight loss, at the cost of higher discontinuation rates. On convenience, orforglipron is the cleaner option of the two oral formulations.

Self-pay price comparison: Foundayo $149/month versus Wegovy Pill starter dose $199/month (NovoCare as of May 2026). The savings compound: approximately $1,800/year at maintenance dose.

Where it sits in the broader pipeline

Orforglipron is the first oral non-peptide GLP-1 to reach the market. Pfizer's danuglipron is behind it in development (Phase 2 results showed higher GI discontinuation rates; dose formulation work continued through 2025). CagriSema (Novo Nordisk, GLP-1 plus amylin) and retatrutide (Lilly, triple GLP-1/GIP/glucagon agonist) are both injectable and target higher efficacy ceilings than current standard. The oral small-molecule class, for now, belongs to Lilly.

What is not yet known

Three significant evidence gaps remain at approval:

Cardiovascular outcomes. The SELECT trial established semaglutide's MACE risk reduction in patients with cardiovascular disease. No equivalent cardiovascular outcomes trial for orforglipron has reported. Lilly has a cardiovascular outcomes trial in progress; data are not expected before 2028 at the earliest.

Long-term durability. The ATTAIN-1 trial ran 72 weeks. What happens at years two, three, five is unknown. The injectable GLP-1 literature suggests substantial weight regain on discontinuation — whether orforglipron behaves differently has not been tested.

Drug interaction profile at scale. The oral contraceptive warning emerged from the trial programme. As Foundayo reaches a larger population of patients on complex medication regimens, additional interaction signals may emerge through post-market pharmacovigilance. Review the full prescribing information with your prescriber and pharmacist.

Pricing and access as of May 2026

LillyDirect began shipping April 6, 2026. Retail pharmacy and telehealth platform availability is rolling out through mid-2026. Insurance formulary placement — and whether your plan requires prior authorisation — varies by payer and plan. The cheapest routes for insured patients are tracked on our cheapest ways to get Wegovy and GLP-1s page, which we update monthly with verified prices.

Telehealth platforms that prescribe GLP-1 medications are being updated to include Foundayo. Compare prescriber options at our GLP-1 provider comparison.

The bottom line

Orforglipron is a genuinely new category: the first oral GLP-1 that works like an oral drug, not a peptide requiring pharmaceutical scaffolding to survive the gut. The ATTAIN clinical programme is robust. The 12.4% weight loss at 72 weeks is real, reproducible across doses, and reproducible across the ATTAIN-MAINTAIN switching cohort.

The honest limitations: it is not as potent as injectable tirzepatide or high-dose semaglutide. It has no cardiovascular outcomes data. The GI side effect burden during dose escalation is comparable to other GLP-1s and resolves for most patients — but approximately 1 in 10 patients discontinued at the highest dose due to side effects in the trials.

For patients who have been waiting for an oral option that behaves like a normal daily pill, that trade-off may be entirely worth making. That is a judgement your prescriber is best positioned to help you reach.

Pricing data sourced from LillyDirect and NovoCare as of May 2026. Prices are subject to change; check manufacturer sites for current figures. This article is editorial-only and does not constitute medical advice. Per our reviewer policy, clinical claims will be reviewed by an ABOM-certified physician before Batch 3 publication; current content is editorially sourced from published trial data and FDA labelling.